Electroconvulsive Therapy (ECT)

What it is

Electroconvulsive therapy is the oldest somatic treatment in psychiatry still in routine use and, by most measures, the single most effective acute treatment for severe depression. Introduced by Cerletti and Bini in 1938, it has survived nearly a century of pharmacological competition because nothing has surpassed it for the sickest patients. Modern ECT bears little resemblance to its cultural caricature: it is delivered under general anesthesia with a muscle relaxant and oxygenation, and the therapeutic agent is a controlled, generalized seizure — brief, monitored, and physically unremarkable to observe. The enduring tension of ECT is that its efficacy and its stigma are both near the top of anything in psychiatry, and the stigma demonstrably limits access to a treatment that is, for some presentations, life-saving.

How it works

The mechanism of ECT remains incompletely understood, which is itself instructive: a treatment can be highly effective and well-characterized clinically while its mode of action stays partly opaque. Several mechanistic accounts have empirical support and are likely complementary rather than competing.

The strongest and most thematically important is the neuroplastic/neurotrophic account. ECT robustly increases BDNF and, across a course of treatment, produces measurable increases in hippocampal and amygdalar volume (Nordanskog and colleagues; meta-analytic confirmation by Takamiya and colleagues, 2018), consistent with enhanced neurogenesis and synaptic remodeling seen in animal models. This places ECT squarely on the neuroplasticity/BDNF final common pathway that this library treats as its downstream convergence point — ECT may be the most powerful pro-plasticity intervention in clinical psychiatry.

A second account is the anticonvulsant hypothesis (Sackeim): the antidepressant effect tracks with the progressive rise in seizure threshold and increase in inhibitory, GABAergic tone across a treatment course, linking efficacy to the brain's homeostatic response to repeated seizures. Additional contributions come from neuroendocrine normalization (HPA-axis recalibration) and network/connectivity changes, including normalization of the subgenual cingulate and default-mode connectivity that figure in the DMN circuit account.

The evidence

ECT's efficacy is unusually well established. The UK ECT Review Group's meta-analysis (2003) confirmed that real ECT is more effective than simulated ECT and more effective than pharmacotherapy. Remission rates in treatment-resistant depression typically fall in the 50–70% range, and are higher still in psychotic (delusional) depression, where ECT is arguably the treatment of choice. The CORE study program (Kellner and colleagues) documented high remission rates with bitemporal ECT and, critically, addressed the field's central practical problem — relapse.

That problem is durability: response to acute ECT is excellent, but relapse without continuation treatment is high. The solution is either continuation pharmacotherapy — the combination of nortriptyline and lithium outperformed placebo and either agent alone (Sackeim and colleagues, 2001) — or continuation/maintenance ECT, with the PRIDE study supporting maintenance approaches in elderly patients. ECT is an acute and maintenance strategy, not a one-time cure.

Indications

ECT's indications cluster around severity, urgency, and specific syndromes. It is used for severe and treatment-resistant unipolar and bipolar depression; for psychotic depression, where it is especially effective; for catatonia, where the response can be dramatic and rapid; for acute, high suicidality and for depression with food refusal or severe malnutrition, where speed matters; for mania refractory to medication; for neuroleptic malignant syndrome; and during pregnancy, when the risks of untreated severe illness or of pharmacotherapy favor ECT. In several of these — catatonia, psychotic depression with imminent risk — ECT is reasonably considered first-line rather than a last resort.

Practical considerations

Technique materially shapes the risk–benefit balance. Electrode placement trades efficacy against cognitive burden: bitemporal placement is the most efficacious and the most cognitively costly; right unilateral (RUL) placement spares cognition but requires adequate dosing (roughly six times the seizure threshold) to match efficacy. Pulse width is the other key lever: ultrabrief-pulse RUL ECT markedly reduces cognitive side effects with efficacy approaching that of standard brief-pulse stimulation (Sackeim and colleagues, 2008). A typical acute course runs two to three treatments weekly for six to twelve sessions.

The dominant concern is cognition. Transient post-ictal confusion and anterograde amnesia are common and resolve; retrograde amnesia, particularly for autobiographical memories around the treatment period, is the side effect patients most fear and can occasionally persist. The reassuring counterweight is Semkovska and McLoughlin's meta-analysis (2010), which found that most cognitive domains recover to or above baseline within about two weeks of a course's end — the acute cognitive effects are largely transient. There is no credible evidence that ECT causes structural brain damage. Other risks are those of brief general anesthesia, with very low mortality (on the order of one per tens of thousands of treatments).

The emerging refinement: magnetic seizure therapy

Magnetic seizure therapy (MST) is the most important emerging development in convulsive treatment. Rather than passing current through the scalp, MST uses high-output magnetic pulses to induce a more focal seizure under anesthesia, with the goal of avoiding the spread into deep medial-temporal memory structures thought to drive ECT's amnestic effects. Early controlled work (Lisanby, Daskalakis, and colleagues) suggests antidepressant efficacy approaching that of ECT with a meaningfully better cognitive profile — faster reorientation and less amnesia. MST remains investigational and not FDA-cleared, but it is the clearest attempt to retain ECT's convulsive efficacy while shedding its cognitive cost.

The convergence

ECT anchors this series at the high-efficacy, high-invasiveness end of the spectrum and connects to the library's core themes more directly than any drug. Its volumetric and BDNF effects make it the strongest clinical evidence for the neuroplasticity/BDNF convergence; its connectivity effects tie to the DMN and neuroimaging biomarker literatures; and its seizure-based, glutamate- and GABA-modulating action links to the glutamatergic account it shares with rapid-acting agents like ketamine. Within this series, ECT is the efficacy benchmark against which TMS and the device therapies are measured.

Caveats — load-bearing, not decorative

Three caveats define honest practice. First, durability: acute efficacy does not translate into lasting remission without a deliberate continuation strategy, and failing to plan for relapse is the most common clinical error. Second, the cognitive trade-off is real, not a myth to be dismissed — while most effects are transient and modern technique mitigates them, persistent autobiographical memory gaps occur in a minority. Third, mechanism remains partly unknown, which should induce appropriate humility: we know ECT works far better than we know why, and confident single-mechanism explanations overstate the evidence.

Bottom line

ECT is the most effective acute treatment for severe, psychotic, and catatonic depression, and it is the clearest clinical demonstration of this library's neuroplasticity convergence — a treatment that measurably grows hippocampal volume and raises BDNF. Its limitations are durability (it requires a continuation plan) and cognitive side effects (real but largely transient and technique-dependent), and its greatest practical problem is paradoxical under-utilization driven by stigma. Magnetic seizure therapy represents a credible path toward preserving its efficacy while reducing its cognitive cost. For the right patient — severe, psychotic, catatonic, acutely suicidal, or unable to tolerate medication — ECT is not a last resort but a first-line, potentially life-saving intervention.

Selected references

1. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003.
2. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007.
3. Sackeim HA, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy. JAMA. 2001.
4. Sackeim HA, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of ECT. Brain Stimul. 2008.
5. Kellner CH, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention (CORE). Arch Gen Psychiatry. 2006.
6. Kellner CH, et al. Right unilateral ultrabrief pulse ECT in geriatric depression (PRIDE). Am J Psychiatry. 2016.
7. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010.
8. Nordanskog P, et al. Increase in hippocampal volume after electroconvulsive therapy in patients with depression. J ECT. 2010.
9. Takamiya A, et al. Effect of electroconvulsive therapy on hippocampal and amygdala volumes: systematic review and meta-analysis. Br J Psychiatry. 2018.
10. Bouckaert F, et al. ECT: its brain enabling effects — a review of electroconvulsive therapy-induced structural brain plasticity. J ECT. 2014.
11. Bolwig TG. How does electroconvulsive therapy work? Theories on its mechanism. Can J Psychiatry. 2011.
12. Petrides G, et al. ECT combined with pharmacotherapy in major depression. J ECT. 2001.
13. Weiner RD, Reti IM. Key updates in the clinical application of electroconvulsive therapy. Int Rev Psychiatry. 2017.
14. McCall WV, et al. Ultrabrief pulse RUL ECT: efficacy and cognitive outcomes. J ECT. 2017.
15. Lisanby SH, et al. Magnetic seizure therapy of major depression. Arch Gen Psychiatry. 2001.
16. Daskalakis ZJ, et al. Magnetic seizure therapy for treatment-resistant depression. Neuropsychopharmacology. 2020.
17. Abrams R. Electroconvulsive Therapy. 4th ed. Oxford University Press; 2002.
18. Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry. 2009.
19. Husain MM, et al. Speed of response and remission in major depressive disorder with acute ECT (CORE). J Clin Psychiatry. 2004.
20. Tor PC, et al. A systematic review and meta-analysis of brief versus ultrabrief pulse ECT. J Clin Psychiatry. 2015.